GSK presents positive trial data for lung cancer drug Jideytro

GSK revealed strong trial outcomes for Jideytro (zidesamtinib), a lung cancer medication, on April 16, 2026. The data emerged from the ARROS-1 trial, which scrutinized patients diagnosed with ROS1-positive non-small cell lung cancer who hadn't been treated with a tyrosine kinase inhibitor previously. The results were presented at the 2026 World Conference on Lung Cancer held in Seoul, South Korea.

Out of 94 patients who hadn't taken any medication before, zidesamtinib achieved a 94% objective response rate during a median follow-up period of 15.2 months. Among these, 15% experienced a complete response. The treatment also showed an 90% progression-free survival rate at 12 months. However, neither the median duration of response nor median progression-free survival had been reached at the time of the analysis.

Ten patients with brain metastases at the beginning of the trial responded positively to the treatment, with 70% achieving full clearance of the brain tumors. By 12 months, 78% of these patients still had an intracranial response. The most frequent side effects included peripheral edema, weight gain, increase in blood creatine phosphokinase, altered taste, and increase in aspartate aminotransferase. These events led to dose reductions in 11% of patients and discontinuation in 1%.

This trial is a global, single-arm phase I/II study focusing on locally advanced or metastatic ROS1-positive non-small cell lung cancer. The analysis was completed on April 16, 2026. Although zidesamtib received FDA approval in July 2026 for patients with ROS1-positive non-small cell lung cancer who had previously been treated with a tyrosine kinase inhibitor, it is not currently approved for first-line therapy.

ROS1 mutations are present in around 2% of non-small cell lung cancers, leading to an estimated 50,000 new diagnoses each year worldwide.